Join Growin Stock Community!

Argenx seARGX.US Overview

US StockHealthcare
(No presentation for ARGX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ARGX AI Insights

ARGX Overall Performance

ARGX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ARGX Recent Performance

-1.10%

Argenx se

0.05%

Avg of Sector

-0.31%

S&P500

ARGX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ARGX Key Information

ARGX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ARGX Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Price of ARGX

ARGX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ARGX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
6.70
PE Ratio (TTM)
32.80
Forward PE
-
PS Ratio (TTM)
11.17
PB Ratio
7.78
Price-to-FCF
99.13
METRIC
VALUE
vs. INDUSTRY
Gross Margin
88.98%
Net Margin
23.86%
Revenue Growth (YoY)
-9.42%
Profit Growth (YoY)
29.41%
3-Year Revenue Growth
11.37%
3-Year Profit Growth
31.60%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
6.70
PE Ratio (TTM)
32.80
Forward PE
-
PS Ratio (TTM)
11.17
PB Ratio
7.78
Price-to-FCF
99.13
Gross Margin
88.98%
Net Margin
23.86%
Revenue Growth (YoY)
-9.42%
Profit Growth (YoY)
29.41%
3-Year Revenue Growth
11.37%
3-Year Profit Growth
31.60%

  • When is ARGX's latest earnings report released?

    The most recent financial report for Argenx se (ARGX) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ARGX's short-term business performance and financial health. For the latest updates on ARGX's earnings releases, visit this page regularly.

  • Where does ARGX fall in the P/E River chart?

    According to historical valuation range analysis, Argenx se (ARGX)'s current price-to-earnings (P/E) ratio is 27.16, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of ARGX?

    According to the latest financial report, Argenx se (ARGX) reported an Operating Profit of 201.06M with an Operating Margin of 21.21% this period, representing a growth of 244.77% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ARGX's revenue growth?

    In the latest financial report, Argenx se (ARGX) announced revenue of 947.96M, with a Year-Over-Year growth rate of 5.1%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ARGX have?

    As of the end of the reporting period, Argenx se (ARGX) had total debt of 43.15M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ARGX have?

    At the end of the period, Argenx se (ARGX) held Total Cash and Cash Equivalents of 2.09B, accounting for 0.29 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ARGX's EPS continuing to grow?

    According to the past four quarterly reports, Argenx se (ARGX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 6.85. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ARGX?

    Argenx se (ARGX)'s Free Cash Flow (FCF) for the period is 432.61M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 444.8% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.